Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph

Physiological Reports

Volumn 2, Issue 3, 2014, Pages

  Wang, Fei ^a   Kohan, Alison B ^a   Henry Dong, H ^b   Yang, Qing ^a   Xu, Min ^a   Huesman, Sarah ^a   Lou, Danwen ^a   Hui, David Y ^a   Tso, Patrick ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

ApoC III; Apolipoproteins; Dietary fat absorption; Intestine

Indexed keywords

APOLIPOPROTEIN C3; CHYLOMICRON; MESSENGER RNA; MONOACYLGLYCEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ESTERIFICATION; HYPERTRIGLYCERIDEMIA; INTESTINE LYMPHATIC TISSUE; ISOTOPE LABELING; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THIN LAYER CHROMATOGRAPHY; TRANSGENIC MOUSE;

EID: 85009062705     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.247     Document Type: Article

References (41)

1. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, et al. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
2. Aalto-Setälä, K., P. H. Weinstock, C. L. Bisgaier, L. Wu, J. D. Smith, and J. L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J. Lipid Res. 37: 1802-1811.
3. Altomonte, J., L. Cong, S. Harbaran, A. Richter, J. Xu, M. Meseck, et al. 2004. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J. Clin. Invest. 114: 1493-1503.
4. Blankenhorn, D. H., P. Alaupovic, E. Wickham, H. P. Chin, and S. P. Azen. 1990. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts Lipid and nonlipid factors. Circulation 81: 470-476.
5. Booth, C. C., D. Alldis, and A. E. Read. 1961. Studies on the site of fat absorption. Gut 2: 168-174.
6. Brown, W. V., R. I. Levy, and D. S. Fredrickson. 1969. Studies of the proteins in human plasma very low density lipoproteins. J. Biol. Chem. 244: 5687-5694.
7. Cohn, J. S. J., M. Tremblay, R. Batal, H. Jacques, C. Rodriguez, G. Steiner, et al. 2004a. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis 177: 137-145.
8. Cohn, J. S., B. W. Patterson, K. D. Uffelman, J. Davignon, and G. Steiner. 2004b. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J. Clin. Endocrinol. Metab. 89: 3949-3955.
9. Coleman, R. 2004. Enzymes of triacylglycerol synthesis and their regulation. Prog. Lipid Res. 43: 134-176.
10. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
11. Fredenrich, A., L. M., Giroux, M., Tremblay, L., Krimbou, J., Davignon, and J. S.Cohn. 1997. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J. Lipid Res. 38: 1421-1432.
12. Gangabadage, C. S., J. Zdunek, M. Tessari, S. Nilsson, G. Olivecrona, and S. S. Wijmenga. 2008. Structure and dynamics of human apolipoprotein CIII. J. Biol. Chem. 283: 17416-17427.
13. Gerritsen, G., P. C. N. Rensen, K. E. Kypreos, V. I. Zannis, L. M. Havekes, and K. Willems van Dijk. 2005. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. J. Lipid Res. 46: 1466-1473.
14. Ginsberg, H. N. and W. V. Brown. 2011. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler. Thromb. Vasc. Biol. 31: 471-473.
15. Guo, Q., R. K. Avramoglu, and K. Adeli. 2005. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 54: 689-697.
16. Haddad, I. A., J. M. Ordovas, T. Fitzpatrick, and S. K. Karathanasis. 1986. Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes. J. Biol. Chem. 261: 13268-13277.
17. Hokanson, J. E., G. L. Kinney, S. Cheng, H. A. Erlich, A. Kretowski, and M. Rewers. 2006. Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes. Diabetes 55: 834-838.
18. Ito, Y., N. Azrolan, A. O’Connell, A. Walsh, and J. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249: 790-793.
19. Kinnunen, P. K. and C. Ehnolm. 1976. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 65: 354-357.
20. Kohan, A. B., F. Wang, X. Li, S. Bradshaw, Q. Yang, J. L. Caldwell, et al. 2012. Apolipoprotein A-IV regulates chylomicron metabolism-mechanism and function. Am. J. Physiol. Gastrointest. Liver Physiol. 302: G628-G636.
21. Kumar, N. S. and C. M. Mansbach II. 1999. Prechylomicron transport vesicle: isolation and partial characterization. Am. J. Physiol. 276: G378-G386.
22. Landis, B. A., F. S. Rotolo, W. C. Meyers, A. B. Clark, and S. H. Quarfordt. 1987. Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase. Am. J. Physiol. 252: G805-G810.
23. Lee, S.-J., H. Campos, L. A. Moye, and F. M. Sacks. 2003. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler. Thromb. Vasc. Biol. 23: 853-858.
24. Lenich, C., P. Brecher, S. Makrides, A. Chobanian, and V. I. Zannis. 1988. Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues. J. Lipid Res. 29: 755-764.
25. Lo, C. M., B. K. Nordskog, A. M. Nauli, S. Zheng, S. B. Vonlehmden, Q. Yang, et al. 2008.Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation?. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G344-G352.
26. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
27. Mann, C. J., A. A. Troussard, F. T. Yen, N. Hannouche, J. Najib, J. C. Fruchart, et al. 1997. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J. Biol. Chem. 272: 31348-31354.
28. Mansbach, C. M., II, and F. Gorelick. 2007. Development and physiological regulation of intestinal lipid absorption II Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G645-G650.
29. McConathy, W. J., J. C. Gesquiere, H. Bass, A. Tartar, J. C. Fruchart, and C. S. Wang. 1992. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid Res. 33: 995-1003.
30. Qu, S., G. Perdomo, D. Su, F. M. D’Souza, N. S. Shachter, and H. H. Dong. 2007. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J. Lipid Res. 48: 1476-1487.
31. Rahim, A., E. Nafi-valencia, S. Siddiqi, R. Basha, C. C. Runyon, and S. A. Siddiqi. 2012. Proteomic analysis of the very low density lipoprotein (VLDL) transport vesicles. J. Proteomics 75: 2225-2235.
32. Roggin, G. M., F. L. Iber, and W. G. Linscheer. 1972. Intraluminal fat digestion in the chronic alcoholic. Gut 13: 107-111.
33. Sacks, F. M., P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, et al. 2000. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102: 1886-1892.
34. Schonfeld, G., P. K. George, J. Miller, P. Reilly, and J. Witztum. 1979. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 28: 1001-1010.
35. Sehayek, E. and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266: 18259-18267.
36. Sundaram, M., S. Zhong, M. Bou Khalil, P. H. Links, Y. Zhao, J. Iqbal, et al. 2010a. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J. Lipid Res. 51: 150-161.
37. Sundaram, M., S. Zhong, M. Bou Khalil, H. Zhou, Z. G. Jiang, Y. Zhao, et al. 2010b. Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J. Lipid Res. 51: 1524-1534.
38. Wu, A. L. and H. G. Windmueller. 1978. Identification of circulating apolipoproteins synthesized by rat small intestine in vivo. J. Biol. Chem. 253: 2525-2528.
39. Xiao, C., J. Hsieh, K. Adeli, and G. F. Lewis. 2011. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am. J. Physiol. Endocrinol. Metab. 301: E429-E446.
40. Zheng, C., C. Khoo, K. Ikewaki, and F. M. Sacks. 2007. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J. Lipid Res. 48: 1190-1203.
41. Zheng, C., C. Khoo, J. Furtado, and F. M. Sacks. 2010. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 121: 1722-1734.